Results 1 to 10 of about 33,732 (139)

Remdesivir

Reactions Weekly, 2023
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus ...
Bakheit, Ahmed H., Darwish, Hany, Darwish, Ibrahim A., Al-Ghusn, Ahmed I.   +3 more
  +17 more sources

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential. [PDF]

PLoS ONE
FDA approved remdesivir, which was though very effective against SARS-corona virus in cell culture system but in human its efficacy was below 10%, as reported. The main reasons are due to the poor stability of remdesivir in presence plasma.
Ashok Chakraborty, Anil Diwan, Vijetha Chiniga, Vinod Arora, Yogesh Thakur, Jayant Tatake, Rajesh Pandey, Preetam Holkar, Neelam Holkar   +8 more
doaj   +2 more sources

Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants [PDF]

Clinical and Translational Science
Remdesivir is an intravenous antiviral approved worldwide for the treatment of COVID‐19 in adults and children. Remdesivir, as a prodrug inhibitor of RNA polymerase, undergoes intracellular activation to form the active metabolite along with 2 inactive ...
Jack Chang, Aryun Kim, Rita Humeniuk, Naveed A. Shaik, Helen Winter, Chi‐Chi Peng, Deqing Xiao, Mazin Abdelghany, Joe Llewellyn, Santosh Davies, Kandace Golden, Shuguang Chen, Robert H. Hyland, Luzelena Caro   +13 more
doaj   +2 more sources

Remdesivir

Reactions Weekly, 2022
  +16 more sources

Remdesivir [PDF]

Hospital Pharmacy, 2021
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Terri L. Levien, Danial E. Baker
openaire   +3 more sources

Clinical Outcomes of Remdesivir in Moderate and Severe Cases of COVID-19: A Retrospective Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: Remdesivir is a nucleotide analogue prodrug that perturbs viral replication. Remdesivir has been used in various trials previously for the treatment of Coronavirus Disease 2019 (COVID-19).
Ruth Priya Senthiappan, Archana A Dambal, Mohan Kashinkunti, Kiran R Aithal, Rajendra Kumar Parakh, Bhargav Vuppumalla   +5 more
doaj   +1 more source

Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Purpose. Remdesivir and its active metabolite are predominantly eliminated via renal route; however, information regarding renal uptake transporters is limited.
Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano, Takaaki Abe, Hiroaki Yamaguchi   +4 more
doaj   +1 more source

Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys

Frontiers in Pharmacology, 2021
Aim: Kidney impairment is observed in patients with COVID-19. The effect of anti-COVID-19 agent remdesivir on kidneys is currently unknown. We aimed to determine the effect of remdesivir on renal fibrosis and its downstream mechanisms.Methods: Remdesivir
Lin Xu, Lin Xu, Lin Xu, Lin Xu, Bo Tan, Di Huang, Di Huang, Di Huang, Di Huang, Meijie Yuan, Meijie Yuan, Tingting Li, Tingting Li, Ming Wu, Ming Wu, Ming Wu, Ming Wu, Chaoyang Ye, Chaoyang Ye, Chaoyang Ye, Chaoyang Ye   +20 more
doaj   +1 more source

Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics

Frontiers in Immunology, 2022
The SARS-CoV-2 virus needs multiple copies for its multiplication using an enzyme RNA-dependent RNA polymerase (RdRp). Remdesivir inhibits viral RdRp, controls the multiplication of the virus, and protects patients.
Bhaswati Chatterjee, Suman S. Thakur
doaj   +1 more source

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis

Therapeutic Advances in Drug Safety, 2021
Introduction: Remdesivir, an experimental antiviral drug has shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both in vitro and in vivo .
Chenchula Santenna, Kota Vidyasagar, Krishna Chaitanya Amarneni, Sai Nikhila Ghanta, Balakrishnan Sadasivam, Saman Pathan, R. Padmavathi   +6 more
doaj   +1 more source